JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB180880

Hela-DFO treated (0.5mM, 24h) Nuclear Lysate

Be the first to review this product! Submit a review

|

(1 Publication)

Hela-DFO treated (0.5mM, 24h) Nuclear Lysate. View our extensive range of validated lysates from normal and diseased human, mouse and rat tissue.
4 Images
Western blot - Hela-DFO treated (0.5mM, 24h) Nuclear Lysate (AB180880)
  • WB

Unknown

Western blot - Hela-DFO treated (0.5mM, 24h) Nuclear Lysate (AB180880)

Abcam recommends using 5% milk as the blocking agent, decreasing to 2% milk during primary and secondary incubation. Abcam welcomes customer feedback and would appreciate any comments regarding this product and the data presented above.

All lanes:

Western blot - Anti-HIF-1 alpha antibody [EP1215Y] (<a href='/en-us/products/primary-antibodies/hif-1-alpha-antibody-ep1215y-ab51608'>ab51608</a>) at 1/2000 dilution

Lane 1:

Western blot - HeLa nuclear extract lysate (<a href='/en-us/products/cell-lysates/hela-nuclear-extract-lysate-ab150036'>ab150036</a>) at 40 µg

Lane 2:

Western blot - Hela-DFO treated (0.5mM, 24h) Nuclear Lysate (ab180880) at 40 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/10000 dilution

Predicted band size: 92 kDa

Observed band size: 110 kDa

true

Exposure time: 8min

Western blot - Hela-DFO treated (0.5mM, 24h) Nuclear Lysate (AB180880)
  • WB

Lab

Western blot - Hela-DFO treated (0.5mM, 24h) Nuclear Lysate (AB180880)

We recommend using 5% milk in TBST as the blocking agent, decreasing to 2% milk in TBST during primary and secondary antibody incubation.

Blots were developed with Goat Anti-Mouse IgG H&L (HRP) preadsorbed (ab97040) secondary antibody

All lanes:

Western blot - Anti-HIF-1 alpha antibody [H1alpha67] (<a href='/en-us/products/primary-antibodies/hif-1-alpha-antibody-h1alpha67-ab1'>ab1</a>) at 5 µg/mL

Lane 1:

Western blot - HeLa nuclear extract lysate (<a href='/en-us/products/cell-lysates/hela-nuclear-extract-lysate-ab150036'>ab150036</a>) at 40 µg

Lane 2:

Western blot - Hela-DFO treated (0.5mM, 24h) Nuclear Lysate (ab180880) at 40 µg

Lane 3:

HeLa nuclear control at 40 µg

Lane 4:

HeLa nuclear DFO treated at 40 µg

Lane 5:

Western blot - Recombinant Human HIF-1 alpha protein (<a href='/en-us/products/proteins-peptides/recombinant-human-hif-1-alpha-protein-ab154478'>ab154478</a>) at 0.001 µg

Secondary

All lanes:

Western blot - Goat Anti-Mouse IgG H&L (HRP) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-mouse-igg-h-l-hrp-preadsorbed-ab97040'>ab97040</a>) at 1/10000 dilution

Predicted band size: 92 kDa

false

Exposure time: 20min

Western blot - Hela-DFO treated (0.5mM, 24h) Nuclear Lysate (AB180880)
  • WB

Unknown

Western blot - Hela-DFO treated (0.5mM, 24h) Nuclear Lysate (AB180880)

false

Western blot - Hela-DFO treated (0.5mM, 24h) Nuclear Lysate (AB180880)
  • WB

Unknown

Western blot - Hela-DFO treated (0.5mM, 24h) Nuclear Lysate (AB180880)

false

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Disease

Adenocarcinoma

Product details

We recommend aliquoting the extracts into single use fractions and then storing them at -80°C.

The cells were treated for 24 hours with a 0.5mM solution of Deferoxamine (DFO). DFO is used as a hypoxia-mimetic agent to stabilize Hypoxia Inducible Factor 1 (HIF-1). DFO stabilizes HIF-1 through the inhibition of Prolyl Hydroxylases (PHDs) which target HIF-1 through degradation. The mechanism of DFO inhibition is likely through the chelation of Fe2+ bound to the active site of PHD which is required for enzymatic activity.

Properties and storage information

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 9:4296 PubMed30327466

2018

Early redox activities modulate Xenopus tail regeneration.

Applications

Unspecified application

Species

Unspecified reactive species

Fernando Ferreira,VijayKrishna Raghunathan,Guillaume Luxardi,Kan Zhu,Min Zhao
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com